The global dapagliflozin market is driven by the increasing prevalence of diabetes, heart failure, and chronic kidney disease (CKD). According to the International Diabetes Federation (IDF), approximately 537 million adults aged 20-79 were living with diabetes in 2021, with the number expected to rise to 643 million by 2030. Furthermore, heart failure affects over 64 million people globally, with nearly half showing reduced ejection fraction, a key indication for dapagliflozin use. Chronic kidney disease impacts nearly 10% of the global population, with millions remaining undiagnosed due to asymptomatic progression. The efficacy of dapagliflozin in managing glucose levels, reducing cardiovascular risks, and slowing CKD progression has positioned it as a critical therapeutic agent, particularly in regions with a high burden of these conditions, such as Asia-Pacific and North America.
